THLD News Alert Threshold Pharmaceuticals (THLD) 2.93 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Threshold Pharmaceuticals (THLD) 2.93 $THLD

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)

Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD" in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting
Marketwired - Sat Dec 06, 11:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade(R)) and low-dose dexamethasone ("TBorD" for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California (Abstract #2142).
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
Marketwired - Tue Nov 25, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a.m. Eastern Time and at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014, at 11:30 a.m. Eastern Time.
THLD: 2.93 (+0.01)

Are Central Banks Panicking?
Leo Kolivakis - Seeking Alpha - Fri Nov 21, 12:50PM CST
Koh Gui Qing and Jason Subler of Reuters report, China surprises with interest rate cut to spur growth : China cut interest rates unexpectedly on Friday, stepping up efforts to support the world's second-biggest economy as it heads towards its...
PGNX: 6.99 (-0.03), BCRX: 11.83 (+0.76), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), IDRA: 3.89 (+0.02), QQQ: 104.30 (+0.09), SGEN: 31.10 (-0.14), XBI: 182.62 (+3.44), TGTX: 16.03 (+0.33), IBB: 299.80 (+5.12), THLD: 2.93 (+0.01), IWM: 119.76 (-0.10), TWTR: 37.61 (+0.04), XOMA: 3.68 (+0.11)

Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
Marketwired - Mon Nov 17, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin(R)) for the treatment of glioblastoma (GBM), the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only U.S. Food and Drug Administration (FDA)-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.
THLD: 2.93 (+0.01)

Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 6.49 (+0.29), AGEN: 3.85 (unch), NVAX: 5.81 (+0.18), ALXN: 181.96 (+3.09), PPHM: 1.40 (+0.01), THLD: 2.93 (+0.01), GSK: 42.85 (+0.11), OMER: 22.09 (+0.48)

Alibaba and Ford are big market movers
AP - Tue Nov 11, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
F: 15.30 (-0.03), SFY: 4.47 (-0.06), THLD: 2.93 (+0.01), SFM: 32.70 (+0.02), ZNGA: 2.71 (-0.01), LUV: 41.66 (+0.68), DRI: 58.42 (-0.09), BABA: 105.95 (+0.43)

Threshold Pharma cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:30AM CST

THLD: 2.93 (+0.01)

Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 8.2% (THLD)
Comtex SmarTrend(R) - Tue Nov 11, 10:11AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 8.2% to $3.23 on 1.6x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 756,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's 0.1%) and outperformed the S&P 500 (8.2% to the S&P's 0.1%) during today's trading.
THLD: 2.93 (+0.01)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:17AM CST

JRJC: 5.81 (-0.11), CODI: 15.99 (-0.11), RAX: 48.24 (+0.45), QIWI: 20.88 (+0.36), MCEP: 6.07 (-0.12), PHMD: 1.46 (-0.03), SFM: 32.70 (+0.02), VSLR: 8.97 (+0.18), VOD: 34.65 (-0.05), LITB: 6.30 (+0.10), PT: 1.21 (-0.01), THLD: 2.93 (+0.01), ZNGA: 2.71 (-0.01)

Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previously Untreated Patients With Metastatic or Locally Advanced Unresectable Soft Tissue Sarcoma
Marketwired - Tue Nov 11, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conference
Marketwired - Mon Nov 10, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. Eastern Time.
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Marketwired - Thu Nov 06, 8:06AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade(R)) in patients with relapsed/refractory multiple myeloma will be presented in a poster at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco, California, from December 6 - 9, 2014 (Abstract #2142).
THLD: 2.93 (+0.01)

Threshold Pharma ups revenues 16% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:43AM CST

THLD: 2.93 (+0.01)

Threshold Pharmaceuticals posts 3Q loss
Automated Insights - Mon Nov 03, 6:06AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Monday reported a third-quarter loss of $7.7 million.
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:05AM CST

THLD: 2.93 (+0.01)

Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Marketwired - Mon Nov 03, 6:05AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin(R) (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) held in Miami, Florida, from November 13-16, 2014.
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Marketwired - Mon Nov 03, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September 30, 2014 was $7.6 million. The net loss for the third quarter ended September 30, 2014 was $7.7 million, which included the operating loss of $7.6 million and non-cash expense of $0.3 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2014, Threshold had $68.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.93 (+0.01)

Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Marketwired - Mon Nov 03, 5:59AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold has a global license and co-development agreement with Merck KGaA, Darmstadt, Germany for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
THLD: 2.93 (+0.01)

Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 10.91 (+0.36), PGNX: 6.99 (-0.03), IDRA: 3.89 (+0.02), THLD: 2.93 (+0.01), FOLD: 7.94 (+0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 99

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 27

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

Director Declaration - Northern 2 VCT PLC

Updated Category News Views 143

Director Declaration - Northern 2 VCT PLC Northern 2 VCT PLC (“the Company”) has announced that Ranjan Ramparia, who currently serves as a non-executive director and audit Chair of the Company, will take on a new role as a non-executive director at Keystone Positive Change Investment Trust plc. Disclosure Compliance In line with the UK Listing Rules, there are no...

Continue Reading
Exploring WisdomTree's Diverse Fund Offerings and Prices

Updated Category News Views 119

Understanding WisdomTree's Daily Fund Prices WisdomTree Issuer plc, renowned for its innovative investment strategies, provides a range of ETF products that cater to various investment needs. The company focuses on not just traditional asset classes but also on megatrends shaping the future. Investors looking to stay updated on their financial assets can explore the daily...

Continue Reading
Atlantic American Corporation Sees Positive Growth in Q1 Results

Updated Category News Views 198

Atlantic American Corporation Achieves Strong Q1 Performance Atlantic American Corporation (NASDAQ: AAME) recently announced its financial results for the first quarter of the year, showcasing a significant turnaround in performance. The company reported a net income of $0.8 million, translating to $0.03 per diluted share. This marks a remarkable recovery from a net loss...

Continue Reading
CTT's Growth in Q3 2024: A Promising Outlook for Q4

Updated Category News Views 80

CTT's Impressive Q3 Performance CTT (CTT.LS) reported a stellar third quarter, showcasing significant revenue growth and a bright outlook for the fourth quarter. As discussed by CEO Joao Bento, the company achieved a remarkable 17.3% increase in revenue, accompanied by a 28.6% rise in EBIT when excluding Financial Services. This transition period highlights CTT's...

Continue Reading
Global Leaders Unite for Climate Justice Summit in NYC

Updated Category News Views 186

Global Leaders Come Together for Climate Justice Summit in NYC The Climate Justice Summit: People Deliver marks a significant kickoff for Climate Week in New York City. This vibrant event will gather a broad spectrum of climate justice advocates from around the world, who will collaborate and share their insights. A coalition of key organizations, including the HBCU Green...

Continue Reading